ImCheck Therapeutics

Partnership since June 2022

ImCheck

In June 2022, LLS made an equity investment in ImCheck Therapeutics to "Support Clinical Development of the ICT01 Program for Blood Cancer Indications."

ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators.

ICT01 is a humanized, anti-BTN3A (also known as CD277) monoclonal antibody that selectively activates γ9δ2 T cells, which are part of the innate immune system that is responsible for immunosurveillance of malignancy and infections. ImCheck's “first-in-class” activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, to overcome resistance to this group of agents.

A clinical trial (EVICTION) is currently enrolling Phase 2 cohort expansion of ICT01 in combination with azacitidine and venetoclax in patients with untreated acute myeloid leukemia (NCT04243499).

For more information about ImCheck, visit www.imchecktherapeutics.com/.

Recent News

  • September 18, 2024 - announced that FDA has granted Fast Track designation to ICT01 in combination with azacitidine and venetoclax for the treatment of AML patients 75 years or older, or who have comorbidities that preclude use of standard intensive induction chemotherapy
  • August 29, 2024 - announced it received EUR 20.18 million in non-dilutive funding as part of the “i-Démo” call for projects under the France 2030 Plan operated by Bpifrance on behalf of the French government.
  • October 16, 2023 - announced updated data from the Phase I dose escalation portion of the EVICTION trial of ICT01, administered as a monotherapy to patients with hematological cancers, primarily AML at the ESMO Congress in an oral session in Madrid. 
  • June 13, 2022 – announced the completion of an upsized $103 million Series C financing to advance clinical program of first-in-human gamma-delta T cell activating antibody and accelerate development of disruptive immunotherapeutic pipeline by bringing on board top-tier global venture funds Earlybird, Andera Partners and Invus and patient organization The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) to prestigious syndicate.